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A B S T R A C T
The prevalence of opioid use disorders among people who are incarcerated is high. People who are released from
incarceration are at increased risk for overdose. The current study details the first year of implementation of a
state-wide medications for addiction treatment (MAT) program in a unified jail and prison setting at the Rhode
Island Department of Corrections in Cranston, Rhode Island. We conducted 40 semi-structured, qualitative in-
terviews with people who were incarcerated and concurrently enrolled in the MAT program. Analysis employed
a general, inductive approach in NVivo 12. We found that a majority of participants discussed program benefits
such as reduced withdrawal symptoms, decreased prevalence of illicit drug use in the facility, improved general
environment at the RIDOC, and increased post-release intentions to continue MAT. Suggested areas of im-
provement include reducing delays to first dose, increasing access to other recovery services in combination with
MAT, improving staff training on stigma, and earlier access to medical discharge planning information prior to
release. Our findings suggest that correctional MAT programs are acceptable to targeted populations and are a
feasible intervention that may be transferable to other states.
1. Introduction
Opioid use disorder (OUD) and overdose have increased dramati-
cally in the United States (US). From 1999 to 2014, drug overdose rates
in the US nearly tripled (Rudd, 2016). Over the past two decades,
nonmedical prescription opioid use contributed substantially to rising
overdose rates (Calcaterra et al., 2013; Cerdá et al., 2013; Kenan et al.,
2012). In more recent years, national initiatives to reduce opioid pre-
scribing have produced modest declines in the number of prescription
opioids dispensed (Dart et al., 2015). However, due in part to these
supply-side interventions, from 2010 to 2014, the rate of heroin-in-
volved overdose deaths in the US increased three-fold (Compton et al.,
2016).
As people with OUD shift from the use of non-medical prescription
opioids to heroin, the epidemic of opioid overdose has been ex-
acerbated by contamination of the heroin supplies with illicitly-manu-
factured fentanyl and related compounds, as well as a shift to fentanyl
use (Centers for Disease Control and Prevention, 2015). Several states
have documented substantial increases in fentanyl-related overdose
fatalities, including Rhode Island (RI) (Centers for Disease Control and
Prevention, 2013; Lozier et al., 2015; Mercado-Crespo et al., 2014). In
2016, 58% of all overdose deaths in RI involved fentanyl—an increase
from 47% in 2015 and less than 5% in earlier years (Rhode Island
Governor’s Overdose Prevention and Intervention Task Force, 2015;
Marshall et al., 2017; Truong et al., 2019).
Individuals with recent criminal justice (CJ) involvement have an
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2. Methods
We conducted 40 semi-structured, qualitative interviews with par-
ticipants in the RIDOC MAT program. Interviews were conducted via
the Evaluating the Implementation and Impact of a Novel Medication
Assisted Treatment Program in a Unified Jail and Prison System (E-
MAT; R21DA044443) study. Inclusion criteria included current en-
rollment in the MAT program, being 18 years old and older, and being
able to read and write in English. The MAT program has the following
major components: 1) screening for opioid use disorder upon intake, 2)
initiating or continuing suboxone, methadone, or naltrexone as clini-
cally appropriate, 3) linking to community MAT upon release (via a
medical discharge planner). In addition, all MAT program participants
are required to attend regular group counseling sessions. The maximum
dose for patients receiving methadone is 120mg unless ordered by a
provider from the MAT service vendor; patients receiving buprenor-
phine have a maximum dose of 16mg unless determined by a provider
that a higher dose is needed. Participants were recruited at the RIDOC
during program group sessions by two research assistants trained in
qualitative interviewing (MP, KP). During the program group sessions,
the study was described, and participants were able to confidentially
sign up for the study and be later contacted for an hour-long interview.
Both interviewers (MP, KP) were female, had conducted research before
in criminal justice settings, and were well versed in how best to build
rapport and to work with people who are incarcerated.
The sample was purposively stratified to proportionally represent
patients’ type of MAT, time of MAT initiation (i.e., prior to vs. during
incarceration), and facility of residence at the RIDOC (e.g., intake,
minimum, and medium security).
All interviews were conducted in a private room without correc-
tional officers present. The interviews were semi-structured and cov-
ered topics such as attitudes toward MAT, experiences in the MAT
program, perceived benefits and challenges of the program, post-release
substance use plans, and fentanyl perceptions. On average, the inter-
views were approximately one hour in length. Interviews were digitally
recorded and later transcribed. All participants received a $25 money
order reimbursement for their time that was deposited into their com-
missary account. The study was approved by the Miriam Hospital’s
Institutional Review Board and the RIDOC Medical Research Advisory
Group.
Qualitative data analysis employed a general inductive approach,
which allows for research to be divided into codes and themes in line
with the research objectives and the questions asked during interviews
(Thomas, 2006). The coding team consisted of five individuals trained
in qualitative research analysis (LBR, MP, KP, AT, AM) who utilized an
initial codebook that mapped onto our study objectives. Four interviews
were cross-coded by all five team members to further refine and add to
the codebook, ensure coder agreement and uniform use of the codes.
After this initial coding exercise, all codes were compiled into a final
codebook, and three members of the coding team (MP, KP, and AT)




Participants ranged from 22 to 66 years old with a mean age of 37.2.
Of those participants, 50% (n=20) were receiving methadone, 47.5%
(n= 19) were receiving buprenorphine, and one person (2.5%) was
receiving depot naltrexone (this breakdown is proportional to the
number of patients at the RIDOC receiving each medication). In total,
50% of participants had started their current MAT prescription in the
community prior to arrest and 50% had initiated their current MAT
prescription while they were incarcerated at the RIDOC. Most partici-
pants were male (70%; n=28) and White (82.5%; n= 33). Five per-
cent (n= 2) were Black, 12.5% (n= 7) identified as belonging to an
“other” racial group, and 10% (n=4) were Hispanic. Participants also
predominantly identified as heterosexual (87.5%, n=35) with (5%;
n=2) identifying as gay and 7.5% (n=3) identifying as bisexual.
Overall, 40% (n= 16) had finished high school, 20% (n= 8) had not
completed high school, and the remainder reported completing edu-
cation beyond a high school degree (40%, n=16). A majority of par-
ticipants reported that before incarceration, they had been using heroin
(95%; n=38); thirty (75%; n= 30) used prescription opioids non-
medically, 21 (53%) used cannabis, 12 (30%) reported non-medical
benzodiazepine use, and 8 (20%) reported having used alcohol when
asked an open-ended question to describe their substance use history in
general.
3.2. MAT program benefits
In general, participants’ reported experiences with the program
were very positive. A majority discussed benefits, such as not having to
go through withdrawal, but many also discussed unexpected benefits,
including decreased prevalence of illicit drugs inside RIDOC, improved
general environment at the RIDOC, and increased post-release inten-
tions to continue MAT.
even greater increase in risk of overdose death during community re-
entry than people who have not been incarcerated as many people 
experience decreased tolerance to opioids after release (Binswanger 
et al., 2011, 2013; Binswanger et al., 2007; Farrell and Marsden, 2008; 
Merrall et al., 2010). In 2014 and 2015, 21% of all fatal overdose 
victims in RI were incarcerated in the two years prior to death, an in-
crease from 9% in 2009 (Brinkley-Rubinstein et al., 2018a,b). In addi-
tion, in 2015, 57% of overdose decedents who had recent criminal 
justice (CJ) involvement experienced a fentanyl-related overdose, an 
increase from 29% in 2014 (Brink ley-Rubinstein et al., 2018a,b). In 
2016, in response to the current opioid epidemic, the evolving fentanyl 
crisis, and the increased risk of overdose among those with recent CJ-
involvement, the RI Department of Corrections (RIDOC) created the 
first-ever, s tatewide corrections-based comprehensive medications for 
addiction treatment (MAT) program that includes access to methadone, 
suboxone, and depot naltrexone combined with behavioral therapy. 
The decision of which medication to use is based upon the patient’s 
needs and preferences.
Providing access to MAT in correctional settings can reduce post-
incarceration illicit opioid use (Connock et al., 2007; Mattick et al., 
2009), criminal behavior (Kinlock et al., 2009), mortality and overdose 
risk (Deck et al., 2009; Degenhardt et al., 2011; Kerr et al., 2007), and 
HIV risk behaviors (MacArthur et al., 2012). Additional social, medical, 
and economic benefits to providing MAT to incarcerated persons with 
OUD are well-documented (Heimer et al., 2006; Mattick et al., 2009; 
McKenzie et al., 2012; Rich et al., 2015; Zaller et al., 2013; Dolan et al., 
2003). The World Health Organization (World Health Organization, 
2009) and the National Institute on Drug Abuse (National Institute on 
Drug Abuse, 2014) endorse the use of MAT to treat OUD in incarcerated 
populations, yet there has been little to no implementation or routini-
zation of MAT in US jail and prison settings (Rich et al., 2015; Vestal, 
2016). In RI, the comprehensive MAT program has been successful in 
reducing post-release overdose and has been cited as a national para-
digm. A recent study by our group found that post-release overdose 
deaths decreased 60.5% among those with recent incarceration and 
induced a 12% decline in overall overdose deaths compared to the year 
before program implementation (Green et al., 2018). In an effort to 
build on these quantitative findings and provide a roadmap for other 
correctional entities who may be contemplating implementing MAT 
programs, the current study describes the perceived benefits and chal-
lenges encountered by participants in the RIDOC’s MAT program.
“It’s helped me big time because last time I was here I struggled
almost half my [sentence]. I was sick as a dog. I just felt awful. Now,
this time around, I don’t have to be like that. I can be normal. I don’t
have to feel sick and feel like I’m half dead. So, I think it’s big. I think
they’re doing good offering that in the prison system now, finally. I
think they should do it in other states.”
Other participants echoed this sentiment and discussed the wide
reach of the program given that many people in the RIDOC were in-
carcerated due to crimes related to their substance use disorder. One
participant, for example, discussed how the program had helped ease
his withdrawal symptoms. This participant perceived that the program
was intended both to help people with substance use disorders and to
reduce recidivism among the broader population. When asked how the
participant would feel without the program in place, the 36-year-old
male participant responded:
“Yeah, I’d be sick. I’d be uncomfortable, and my mind would be all
over the place. It’s 100 percent better. You’re just making things a
lot easier for people. I mean this is jail, don’t get me wrong, but this
[is] medication that doctors give us, you know? So, it’s like, you
guys are doing the right thing. […] Because we’re trying to get our
lives back together. You know people that are on the stuff. So, with
taking that away and shooting guys back to the streets just to put
them back in the same position, and it’s really not the cure for that.
They’re usually here because of substances. Ninety percent, well, I
don’t know the percentage, but most of these cats are here from
stealing or whatever they’re doing, you know. So, you’re helping
them out.”
The participant, therefore, explained that he felt that the program
would reduce recidivism and address the social circumstances sur-
rounding addiction that led to incarceration in the first place. The
participant noted that MAT was merely a medical treatment to a health
condition and would contribute to a reduction in incarceration over
time.
3.2.2. Decreased illicit substances at the RIDOC
Many participants stated that an ancillary benefit to the program
was a lower prevalence of illicit drugs in the facility due to decreased
need to use among people who are incarcerated. When asked how the
environment at the facility would be different without the MAT pro-
gram, one 22-year-old male participant said: “There’d be more drugs.
There’d be a lot more drugs floating around jail, I think. A lot more.
We’re addicts. We’re going to get high. If we want to get high, we’re
going to get high”. The participant perceived that the MAT program
had contributed to a reduction in substance use in the facility, as people
experiencing opioid use disorder would try to curb withdrawal re-
gardless of whether withdrawal management was allowed. Another 41-
year-old male participant similarly stated that his need to use illicit
drugs was no longer an issue:
“Unfortunately, there is drugs in the prison systems and being on
this [MAT], that is not even on my radar. I don’t have to worry about
getting something off somebody and doing that whole criminal ac-
tivity or owing people anything. I do my own program in here, and
I’m good. I don’t need anything else. It’s a blessing. It’s a blessing
that finally people are realizing isn’t the devil.”
Relatedly, another 55-year-old male participant stated that because
of the MAT program, there were fewer overdoses from illicit drugs
among incarcerated people while at RIDOC: “[If there was no MAT
program] there’d be more overdoses, and people would be dropping
like flies because of the potency of the heroin in the street now with
fentanyl. And they would bring it in the system, and people would be
dropping. It would be more people in caskets than anything else.”
3.2.3. Improved facility environment
While discussing the benefits of the MAT program, participants
often discussed a general improvement in the environment at the
RIDOC. For instance, one participant highlighted that fewer people
would be tempted to use illicit substances during incarceration, which
could lead to less violence. When asked to imagine that there was no
MAT program in place, the 22-year-old male participant reported that
conditions in the RIDOC would feel more unsafe:
“If there was no MAT program, it’d be more drugs in the prison, and
with more drugs in the prison, anything is liable to happen. When
people get high, they’re not themselves. I know when I get high, I’m
not myself. I’m actually really mean and like really angry all the
time. So, I mean it can be a lot less safe and probably be more fights,
more violence”.
Another participant speculated that the improvement in the facility
environment would extend to non-MAT program participants. While
discussing the benefits of the program, the 36-year-old male reported:
“When they come in, and [people with OUD are] sick, they’re sick.
They definitely need methadone, and I think it’s great that people
are sick, and they come in here and they can get on something that
helps them. That’s awesome. [People] over there puking on them-
selves, you know what I mean, and like some people don’t do
drugs—they’re disgusted. Like, you’re disgusting, you know I mean?
We don’t want to come into jail and then live with somebody who’s
over there puking. You know what I mean? It’s better for the people
that aren’t on drugs, and it’s better for the people who are on drugs.
It’s better for everybody because nobody’s sick, nobody’s puking
themselves. I’ve been there, you know?”
Relatedly, some participants reported that the MAT program had
eased the burden on staff. For example, one 41-year-old male partici-
pant who was asked about how RIDOC nurses perceived the program
stated:
“I think they understand what the potential could be and is. It’s less
work for them having people not come in and being sick all the time.
They understand how much of a mental thing that is. You almost do
anything to not feel that way. You’ll lie. I had a roommate that faked
having a seizure, a stroke just to get his meds to feel better. I think
they’re a little more sympathetic [after MAT program implementa-
tion].”
This participant reported that other people who were incarcerated
typically needed less care than people who were experiencing with-
drawal symptoms. From this participant’s perspective, reducing the
number of people who were experiencing withdrawal symptoms cre-
ated a more balanced workload for RIDOC staff. Participants therefore
highlighted how the environmental changes at the facility extended
beyond individual participants to other people who were incarcerated
and staff.
3.2.4. Changed post-release substance use intentions
In addition to having positive implications during incarceration,
participants also discussed the personal impact of the MAT program on
post-release plans. Specifically, they focused on how access to MAT at
3.2.1. Incarceration without withdrawal
Most participants stated that avoidance of withdrawal was a major 
benefit o f t he MAT program a t t he RIDOC. As one 36-year-old male 
participant said after being asked about experiences in the program: 
“[The program] definitely helped me to l ike, you know, just regulate 
and get back on the path of, you know, not being sick every day.” The 
participant reported that, relative to prior incarcerations, his experi-
ence of incarceration had improved without withdrawal symptoms. 
Another 33-year-old male participant compared his current experience 
to a previous time he had been incarcerated and lacked access to MAT, 
noting that he felt a reduction in withdrawal symptoms:
“I mean I think, like I said, I think it’s a godsend. I mean I think, you
know, I think they should have this in other prisons especially be-
cause this is the time where a lot of people make the decision on if
they’re going to stay clean or not. Because you gather a little time
under your belt and then you say all right, well, you know, maybe I
will stay clean. And then, well, how am I going to do it? I’ve got, you
know. Or if I get out, I’ll use. You have a little time to step back and
look at things, see the way things are for actually for what they are.
You know? Without a clouded distorted view of that, you know,
with drug fueled way that you’re living out there.”
The participant reported that receiving MAT while at the RIDOC
allowed him to think about abstaining from future substance use. He
noted that his attitude had changed toward reducing substance use over
the period of time that he had been incarcerated and enrolled in
treatment. Another 36-year-old male participant highlighted how ac-
cess to MAT while incarcerated meant that he would not experience
cravings post-release and therefore abated the need to return to illicit
substances:
“Well, I just know that you can get on the program here and stay on
it through your bid, and when you get out, you’re hooked up, and
you don’t have to run to the street, you know. A lot of guys are
coming in, they’d be sick. As soon as they get out, they run right out
and get a bag of dope, and that’s it”.
This sentiment was echoed by the majority of participants who did
not intend to use opioids and other substances post-release; these par-
ticipants instead expressed intention to continue on MAT treatment
post-release through care linkage.
3.3. MAT program areas for improvement
Most participants expressed satisfaction with the program, but many
also had suggestions for optimal program delivery. Suggested areas of
improvement centered on four key themes: reducing delays to first
dose, increasing access to other recovery services in combination with
MAT, increasing [or “improving”] staff training on stigma, and earlier
access to medical discharge planning information prior to release.
3.3.1. First dose delays
The majority of participants did not report delays to accessing MAT
during their incarceration; however, it was an issue for a few partici-
pants. While most participants explained that they had received their
doses in a timely matter, some participants cited delays in receiving
MAT. They discussed how delays undercut the therapeutic benefits of
MAT that would have minimized their withdrawal symptoms. A 35-
year-old male participant who had not been on MAT in the community
before his incarceration also cited delays after specifically requesting
MAT to aid in withdrawal:
“The first day upon intake I told [a nurse] that I was about to be sick
and I needed to speak to someone about getting on methadone be-
cause I came in on nothing. And she said she will let the nurse know
and do I fill out a slip. […] I waited for a few days to get called. I
didn't get called. I sent in a slip, and I ended up getting called down
[…] To interview me at first, and then I saw a doctor a few days
later. The reason it took so long, I guess, is there are lockdowns of
certain things in the jail system that I couldn't go around anything
today. […] It was around a seven, eight, nine – seven to nine-day
process, where I felt like shit the whole time, but I still had to do it.
No sleep.”
For participants who were continuing on a MAT prescription that
originated in the community, some experienced delays based on
inability to report information such as the name of a prescribing doctor
from the past. One 34-year-old participant, for example, noted that he
could only give a vague description of the previous doctor that pre-
scribed him MAT.
“What they did was they said, ‘Oh, since you were on it before it will
be quicker for you to get it’ so I told them I was on it. I didn’t know
the name of the doctor; I just said, ‘Hey, yeah, I was on it.’ I told
them about where it was and the doctor I went to so he said, ‘Oh, I
know where that is.’ He couldn’t get the doctor to release any in-
formation so because of that they made it look like I was lying and
they didn’t give me anything. He said, ‘Oh, well, we can’t prove you
were on it so that doctor is not going to give it to you.’ […] That’s
why it took four months to get on it.”
The participant continued to try to obtain MAT and stated that he
was finally prescribed it after detailing to staff how he had overdosed
four times in the community. The process of coordinating information
between community providers and the RIDOC sometimes impacted
ability to quickly uptake MAT.
3.3.2. Access to recovery strategies in combination with MAT often
requested
When asked what participants would improve about the MAT pro-
gram, many stated that access to other recovery strategies in combi-
nation with MAT would be beneficial. One 31-year-old male participant
noted that he would prefer more frequent and a diverse range of pro-
grams:
“I mean they could have like – they can have more meetings here. I
mean they have only one AA Thursday; every AA [is] Thursday once
a week here. And I never heard anything about NA here to be honest
with you. I mean they could have, like, at least a couple of meetings
a week. I mean they only have one.”
He continued that he would also benefit from more one-on-one
services: “Well, I just think it would be better off if it was like – I would
prefer something more one on one. Like, obviously, they couldn’t do
something in such a large place with so many addicts. You know what I
mean? But at least get a little bit deeper because most addicts aren’t
afraid to talk about it.” Similarly, another 35-year-old male participant
stated the need for either individualized counseling or structured group
meetings: “I mean counseling is good for anybody. Problems or no
problems. It’s a nice sounding board. I mean sometimes you just need to
say something out loud to make it click. I think if we had individual
counseling and a structured group in which we actually cover things,
like, there’s no workbook. If there was a workbook, I think that would
work out great for everything, you know”.
3.3.3. Staff education and training
Many participants stated that there was a need for more staff edu-
cation and training about MAT, the benefits of MAT, and about ad-
diction in general. One 41-year-old male participant said specifically
about correctional officers:
“You know, [the correctional officers] think it’s like free drugs. They
don’t know. They’re uneducated about what it actually is and what
it does. They think that some of these dudes are just on it to get high.
They don’t understand that once you get used to it, you don’t get
anything really off of it.”
Another 52-year-old female participant relayed a similar concern
and underscored the importance of educating correctional officers
about the extended benefits of MAT:
“They [correctional officers] don't believe in it. They're not drug
addicts so they don't understand it for one. If somebody could
counsel - they should have a meeting for them to understand why
we're on it because no one explained to them. They just think well,
RIDOC would improve their ability to discontinue use of illicit sub-
stances during community re-entry. When asked how the program had 
been beneficial, one 31-year-old male participant reported:
we're criminals […] There's a number of them that feel that way. So,
if they was to have counseling or groups that they can sit and learn
why it's beneficial to the people that take it so we don't go out and
die or prevent us from stealing to get drunk. I think it would help the
crime rate and help the death rate, the stealing anyway.”
Another participant discussed how some medical staff weren’t in
favor of the program: “I could count - I know two of them that are
totally against it, could not care less if you take it or not, but for the
majority, they understand. There's a couple that don't understand it and
don't understand why they're helping us with it because they don't get
it. They're not in the drug programs. A little more schooling on it for
them would be better, I think.”
Many participants noted that they felt stigma from nurses and cor-
rectional officers, and when pressed further, explained that they be-
lieved that stigma stemmed from a lack of understanding. After ex-
plaining that they felt looked down upon by nurses and COs, the 26-
year-old male stated: “You see the problem is that I don’t – it’s a lot of
people don’t really understand how addiction is. They think it’s just –
they think that we use just ‘cause we want to get high or we just want to
use. They just don’t understand how the addiction really works.”
3.3.4. More information wanted about linkage before discharge
Participants expressed a desire to learn more about the linkage
process to community-based MAT before discharge. Additionally, par-
ticipants stated that they would prefer to learn about the linkage to care
process before their scheduled meeting with a discharge planner, which
often occurs shortly before release. A 35-year-old male participant
stated:
“I’m really nervous about the leaving part, to be honest. I get my
dose today, but I get out of here tomorrow. I’m like, you know what
I mean? Like, where am I going to get my dose? The discharge part
because I haven’t gone through it, and I don’t know how it’s going to
go; and [the MAT provider who dispenses MAT at RIDOC] only has
so many places where you can go and dose. [The MAT provider who
dispenses MAT at RIDOC] can only do so much to help you get set
up. I mean it’s not like they’re going to hold your hand once you
walk out of here, you know. In my shoes, I’m being told that because
of security issues and what not, I’ll know 48 h in advance before I’m
discharged when I make parole. That’s even like the people who I
work with. Well, they know maybe 48 h in advance before I’m dis-
charged. They say it’s a security issue. Whatever. […]That’s just the
way it is, and while I’m not worried about, you know, going into full
withdrawal in that 48 h.”
This participant expressed anxiety about uncertainty post-release
and thought that knowing well in advance that he had a plan post-
release would ease his worries. Another 30-year-old female participant
discussed how because she had been recently incarcerated and was not
likely to stay in the facility for a long time, she had not received as
many resources as those with longer sentences. She discussed how the
process would be simplified if she was provided with resources to plan
re-entry herself:
Interviewer: Okay. So you have an appointment with the discharge
planner. Why do you think that no one has talked to you about the
program yet?
Respondent: Cause I just got here Friday. […] And I leave in thirty
days and they’re kind of like eh, you know, because a lot of girls are
like going to be here longer.
[…]
Interviewer: So ideally for like people like you who are staying for
a very short period of time and then being released, what kind of
like attention would you have?
[…]
Respondent: You know it would be cool if like you could have a
phone, right, or like there would be a phone that you could use for
just programs or like discharge planner or something like that. […]
Like if I could do it on my own.[…] Do you know what I mean? That
would be helpful.
Interviewer: So like a hotline or something or more hot topics?
Respondent: Or just like more like paperwork with numbers on it or
something where I could like call my family and be like hey. Like
here are the numbers. Can you help me get into it? Because if they
can’t do it for you like you have to have a way to do it yourself like.
[…] I’m sure they could get like a packet with like numbers or
something like.
Another participant stated that he had five weeks left in the facility
before anticipated release. While no one had discussed discharge
planning with him yet, he felt that it was likely that someone would
contact him for an appointment with a discharge planner before his
release. Asked about challenges to continuing MAT, the 34-year-old
male stated:
“If nobody talks to me before I leave and shows me my options of
where to go when I get out, that’s something I’m definitely going to
need, so that might make it difficult. If there is nobody to talk to and
I have to figure it out when I get out - I mean it’s going to make it
difficult. I’ll figure it out, but it would be nice because I know
somebody is in here that can tell me where to go, whether it’s an
inmate or a counselor or somebody. There is a list of places I can go.
I know there is, so I’m hoping I can get it before I leave.”
4. Discussion
Our study documents participants’ mostly positive experiences with
and attitudes toward the MAT program at the RIDOC, with a major
benefit being withdrawal symptom management. Ancillary benefits of
the MAT program included a decreased supply and demand for illicit
drugs at the RIDOC, which contributed, in part, to an improvement in
the RIDOC environment overall. Participants also viewed the program
as positively influencing their post-release substance use intentions,
with many individuals reporting a desire to continue MAT post-release.
This qualitative evaluation of the first statewide program of its kind that
provides access to all three FDA approved MAT options provides insight
into how best to optimize future program implementation at the RIDOC
and other correctional sites.
Despite benefits of the MAT program, participants also noted room
for improvement. Challenges reported by participants included first
dose delays largely related to lapses in communication between com-
munity treatment providers and the RIDOC. This delay in treatment
often led to withdrawal symptoms that reduced potential therapeutic
benefits of MAT. Additionally, participants emphasized preferences for
additional recovery resources while incarcerated and expressed a need
for proactive communication about the medical discharge process post-
release. Many participants expressed the desire to continue MAT in the
community, but this absence of support inhibited their ability to ade-
quately prepare for treatment continuation following release from in-
carceration. Participants also stressed the need for more training and
education for nurses and correctional officers.
Previous studies have found similar findings relating to access to
MAT while incarcerated and reduced substance use after incarceration.
We previously demonstrated that prisoners who had access to metha-
done pre-release were seven times more likely than their untreated
counterparts to seek treatment at a community methadone clinic within
30 days post-release (Rich et al., 2015). Long term outcomes from this
same study showed that individuals who had access to methadone
during incarceration were more likely to be engaged in continuous MAT
treatment one-year post-release (Brinkley-Rubinstein et al., 2018a, b).
Additionally, a study comparing buprenorphine treatment initiation
before and after release revealed a difference in the number of days that
participants continued treatment. Participants who began treatment
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